Acquiring Company
Solventum
Acquired Company
Acera Surgical
EaganSt. LouisManufacturingBiotechnologyHealth CareMedicalMedical DeviceHealthcareDescription
Solventum has completed its acquisition of Acera Surgical as part of its strategy to optimize its portfolio in the healthcare sector. This move is expected to bolster Solventum's presence in the growing synthetic tissue market. The acquisition will complement Solventum's existing product offerings and customer base. This aligns with Solventum's long-range growth plans initiated in 2025.
Who to call at Solventum, and when
When Solventum changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Solventum raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Solventum, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Solventum. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Solventum makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Acera Surgical?
Acera Surgical was acquired by Solventum, based in Eagan. The deal was reported on March 1, 2026. Solventum is a healthcare innovation company dedicated to enabling better, smarter, and safer care. Solventum is publicly traded (SOLV) and operates in Manufacturing.
When did Solventum acquire Acera Surgical?
Solventum's acquisition of Acera Surgical was reported on March 1, 2026. Solventum has completed its acquisition of Acera Surgical as part of its strategy to optimize its portfolio in the healthcare sector. This move is expected to bolster Solventum's presence in the growing synthetic tissue market. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Acera Surgical do?
Acera Surgical is a private bioscience company established in 2013, specializing in engineered materials for regenerative wound care. It has developed innovative synthetic treatment options for soft tissue repair using proprietary electrospinning technology. It is privately held, operating in Healthcare, and is based in St. Louis.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.